Proteomic approach to the diagnosis of acute coronary syndrome: preliminary results.

Cardiac multimarker strategy is recommended by the IFCC, ESC and the ACC for an early risk stratification in non-ST-segment elevation (NSTE) ECG patients with chest pain. A new approach, based on protein biochip array technology, performs simultaneously: cTnI, CK-MB, myoglobin, CAIII, GFBB and FABP using a single chip.
We evaluated the analytical performance of the Randox-Evidence Investigator -biochip cardiac panel according to IFCC recommendations and NCCLS guidelines; a preliminary clinical evaluation was carried out on chest pain NSTE ECG patients, to evaluate the accuracy of the multimarker approach in an early diagnosis of AMI, related to the final diagnosis (ACC/ESC criteria).
Troponin, CK-MB and FABP methods provide reproducible within-run and between-day results (total % CVs from 5.9% to 9.7%), and myoglobin and CAIII methods showed the total % CVs from 16.4% to 25.8%. Our preliminary clinical data suggests that FABP had a better diagnostic performance (sensibility = 100%) than myoglobin (sensibility = 75%) to detect AMI in the first hours after the onset of the chest pain and myoglobin/CAIII ratio (specificity = 92.9%) improved the myoglobin specificity.
Cardiac markers have different diagnostic roles and, in this contest, biochip technology could be an interesting approach supporting clinical expectations.
AuthorsFrancesca Di Serio, Gianfranco Amodio, Enzo Ruggieri, Rosalisa De Sario, Lucia Varraso, Gianfranco Antonelli, Nicola Pansini
JournalClinica chimica acta; international journal of clinical chemistry (Clin Chim Acta) Vol. 357 Issue 2 Pg. 226-35 (Jul 24 2005) ISSN: 0009-8981 [Print] Netherlands
PMID15907829 (Publication Type: Journal Article)
Chemical References
  • Biomarkers
  • Troponin I
  • Acute Disease
  • Biomarkers (analysis)
  • Coronary Disease (diagnosis, metabolism)
  • Humans
  • Proteomics
  • Sensitivity and Specificity
  • Syndrome
  • Troponin I (analysis)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: